6.0(top 2%)
2-year impact
6.5(top 2%)
3-year impact
6.3(top 2%)
5-year impact
6.0(top 2%)
10-year impact
924(top 20%)
PR articles
15.1K(top 10%)
PR citations
56(top 10%)
PR h-index
60(top 10%)
h-index
6.5(top 2%)
extended IF
5.9(top 2%)
2-YI (article-only)
10.4(top 20%)
2-YI (review-only)
4.2(top 20%)
2-YI (comm only)
5.6(top 2%)
2-YI (no self-cite.)
1.2K
documents
20.2K
doc citations

Top Articles

#TitleJournalYearPR Citations
1Epidemiology and Prevention of Prostate CancerEuropean Urology Oncology2021422
2Epidemiology, Screening, and Prevention of Bladder CancerEuropean Urology Oncology2022242
3Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trialEuropean Urology Oncology2020224
4A Systematic Review on the Role of Imaging in Early Recurrent Prostate CancerEuropean Urology Oncology2019154
5Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical TrialEuropean Urology Oncology2018143
6Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand TherapyEuropean Urology Oncology2019135
7Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology2021135
8Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studiesEuropean Urology Oncology2019118
9Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical TrialEuropean Urology Oncology2021118
10Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical ProstatectomyEuropean Urology Oncology2021117
11Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology2020116
12Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature ReviewEuropean Urology Oncology2020115
13Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United StatesEuropean Urology Oncology2019114
14First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisEuropean Urology Oncology2021112
15Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission TomographyEuropean Urology Oncology2018110
16What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic ReviewEuropean Urology Oncology2019100
17Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic ReviewEuropean Urology Oncology201998
18Role of Active Surveillance for Localized Small Renal MassesEuropean Urology Oncology201896
19Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve MenEuropean Urology Oncology201995
20Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate CancerEuropean Urology Oncology201888
21Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines PanelEuropean Urology Oncology202087
22Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysisEuropean Urology Oncology202187
23Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference StandardEuropean Urology Oncology202286
24Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk CalculatorsEuropean Urology Oncology202083
25Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic ReviewEuropean Urology Oncology201981
26Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysisEuropean Urology Oncology202180
27Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)European Urology Oncology202179
28A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)European Urology Oncology202179
29Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel StudyEuropean Urology Oncology202179
30Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate CancerEuropean Urology Oncology201978
31Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysisEuropean Urology Oncology202078
32A European Model for an Organised Risk-stratified Early Detection Programme for Prostate CancerEuropean Urology Oncology202178
33Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell CarcinomaEuropean Urology Oncology202076
34Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment ChoicesEuropean Urology Oncology202076
35Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective CohortEuropean Urology Oncology202076
36First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisEuropean Urology Oncology201975
37The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline PanelEuropean Urology Oncology202074
38A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer PatientsEuropean Urology Oncology202073
39Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerEuropean Urology Oncology202173
40Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer PatientsEuropean Urology Oncology202072
41Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder CancerEuropean Urology Oncology201871
42Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial CarcinomaEuropean Urology Oncology202171
43Intermediate-risk Prostate Cancer: Stratification and ManagementEuropean Urology Oncology202071
44Complications and Adverse Events of Three Magnetic Resonance Imaging–based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled TrialEuropean Urology Oncology201970
45Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation PanelEuropean Urology Oncology202269
46[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the LiteratureEuropean Urology Oncology202268
47The Metabolic Landscape of Prostate CancerEuropean Urology Oncology201967
48TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsEuropean Urology Oncology202267
49Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO TrialEuropean Urology Oncology201866
50Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive ReviewEuropean Urology Oncology201966